Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- BioWa Out-Licenses Kyowa Hakko Kirin’s Technologies and Serves as Its “In-Licensing Window”; “Naked” Mabs to Remain Dominant until 2002
January 27, 2014
- Sanwa Kagaku, Dong-A ST of South Korea Sign License Deal for Nesp Biosimilar in Japan
January 27, 2014
- Novartis Used Interim Report of “Sign” Trial in Tasigna Promotion, Set to Probe Its Involvement in Protocol Drafting
January 24, 2014
- Antidepressant Brintellix Launched in US: Takeda, Lundbeck
January 24, 2014
- Novartis Adds LABA/LAMA Combination Ultibro to Lineup of Breezhaler Products for COPD Using the Same Inhaler
January 24, 2014
- Novartis Pharma Involvement Suspected in Drafting of Sign Trial Protocol
January 23, 2014
- Azilva Remains No.1 in December “Mind Share” Ranking in GP, HP Markets
January 22, 2014
- Japan’s 1st Sublingual Immunotherapy Wins Approval: Torii
January 21, 2014
- Sales Reps Vied over Questionnaire Transfers in Tasigna Trial, Boss OK’ed Incentive Program: Novartis
January 21, 2014
- NBI Receives Approval for Giotrif, Sets to Enter Oncology Field
January 21, 2014
- Nissan Chemical Sues Nichi-Iko, Two Other Companies over Livalo Patent
January 21, 2014
- Novartis Sales Reps Transferred Patient Questionnaires in Investigator-Led Trial
January 20, 2014
- Japan’s First SGLT-2 Inhibitor Suglat Approved: Astellas
January 20, 2014
- Otsuka Files Abilify Once-Monthly Injectable in Japan
January 17, 2014
- Alcon Japan Merges with CIBA Vision
January 17, 2014
- MTPC Files Telavic for Chronic Hepatitis C Genotype 2
January 17, 2014
- FDA Raises Concerns about Ranbaxy’s India Plant with Form 483
January 16, 2014
- Japan Added as Mogamulizumab PIII Study Site for CTCL Patients: Kyowa Kirin
January 16, 2014
- Takeda to Sell BIKEN Varicella Vaccine from February
January 16, 2014
- Swiss Novartis to “Fully Address” Flaws Leading to Criminal Complaint Filing
January 16, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…